Study of the Combination of Binimetinib and Encorafenib in Adolescent Patients With Unresectable or Metastatic BRAF V600-mutant Melanoma
Clinical trial NCT03878719 · TERMINATED
Trial details
- NCT number
- NCT03878719
- Sponsor
- Pfizer
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2020-08-03
- Primary completion
- 2022-08-19
- Enrollment
- 1
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.